SCHEMBL379355

SCHEMBL379355

Cc1noc(-c2ccc(C(=O)N3CCC(C(=O)N[C@@H](C)c4ccc(F)cc4)(c4ccc(F)cc4)CC3)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
BDKRB1 P46663 2/20 0.40
IDO1 P14902 1/20 0.39
KIT P10721 1/20 0.38
HSD11B1 P28845 2/20 0.37
FASN P49327 2/20 0.37
S1PR1 P21453 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MAPT P10636 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378669 0.96 TACR1 (0.41) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL13092251 0.96 BDKRB1 (0.40) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL396983 0.94 TACR1 (0.40) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL378830 0.92 BDKRB1 (0.42) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL13092367 0.92 TACR3 (0.40) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL13092375 0.90 BDKRB1 (0.41) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL13092467 0.90 CTSL (0.42) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL378614 0.90 CTSL (0.42) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL7910518 0.90 CTSL (0.42) TACR3CYP1A2CYP2C9CYP2C19BDKRB1
SCHEMBL378915 0.90 TSHR (0.43) BDKRB1MEN1ALDH1A1KMT2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TACR3 41/4885CYP1A2 1366/4885CYP2C9 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.